levothyroxine sodium 0.175 MG Oral Capsule [Tirosint]

RxCUI
1923049
RxNorm name
levothyroxine sodium 0.175 MG Oral Capsule [Tirosint]
Display name
TIROSINT (Oral Pill)
Full name
levothyroxine sodium 0.175 MG Oral Capsule [Tirosint]
Term type
SBD
Status
Active
Strength
0.175 mg
Dose form
Cap
Route
Oral Pill
Updated
2026-11-04 11:54:15

RxNorm Status History#

Status
Active
Source
RXNORM
Current
YES
Release start
062017
Active start
062017
Multiple ingredient
NO
Branded
YES

Ingredients And Strength#

Ingredient, Strength, Base table
IngredientStrengthBaseBasis of strength
levothyroxine sodium0.175 MG / 1 EACHlevothyroxinelevothyroxine sodium

Dose Form Concepts#

Dose form, RxCUI table
Dose formRxCUI
Oral Capsule316965

Derived Ingredient Concepts#

Ingredient, RxCUI table
IngredientRxCUI
levothyroxine10582

Source Vocabulary Codes#

Code type, Values, Count table
Code typeValuesCountCategory
PRESCRIBABLEY1ATTRIBUTES
RXNAV_STRTirosint 175 MCG Oral Capsule1NAMES
RxNorm Namelevothyroxine sodium 0.175 MG Oral Capsule [Tirosint]1NAMES
RxNorm Synonym
2 linked values
2NAMES
TTYSBD1ATTRIBUTES
SPL_SET_ID7a7ade79-0165-4e31-b84e-667416c00c7e1CODES
RxCUI19230491CODES
MMSL_CODEBD343921CODES

FDA NDC Products And Packages#

Package NDC, Product NDC, Name table
Package NDCProduct NDCNameLabelerApplication
71858-0055-271858-0055Tirosint levothyroxine sodiumIBSA Pharma Inc.NDA021924
71858-0055-471858-0055Tirosint levothyroxine sodiumIBSA Pharma Inc.NDA021924

Drugs@FDA Applications#

Application, NDC, Name table
ApplicationNDCNameMarketing categoryLabeler
NDA02192471858-0055Tirosint levothyroxine sodiumNDAIBSA Pharma Inc.

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 7 matching rows.

NDC11, Source, Active table
NDC11SourceActive
71858005501rxnav_ndcsyes
71858005502rxnav_ndcsyes
71858005504rxnav_ndcsyes
24090050007rxnav_historical
24090050084rxnav_historical
24090050094rxnav_historical
24090050099rxnav_historical

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
TirosintLEVOTHYROXINE SODIUMIBSA Pharma Inc.7a7ade79-0165-4e31-b84e-667416c00c7e2026-03-25Boxed warning, Warnings, Adverse reactionsExact identifier
ndc (package): 71858-0055-4
ndc (package): 71858-0055-2
ndc (product): 71858-0055
ndc11 (package): 71858005501
ndc11 (package): 71858005504
ndc11 (package): 71858005502
rxcui: 1923049

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
7a7ade79-0165-4e31-b84e-667416c00c7eTirosint 175 MCG Oral Capsule [PSN] · levothyroxine sodium 0.175 MG Oral Capsule [Tirosint] [SBD] · Tirosint 0.175 MG Oral Capsule [SY] · Tirosint 175 MCG Oral Capsule [SY]413These highlights do not include all the information needed to use TIROSINT® safely and effectively. See full prescribing information for TIROSINT. TIROSINT® (levothyroxine sodium) capsules, for oral use Initial U.S. Approval: 200020260325

Recently Linked DailyMed Labels#

Set ID, Title, Manufacturer table
Set IDTitleManufacturerEffective
7a7ade79-0165-4e31-b84e-667416c00c7eThese highlights do not include all the information needed to use TIROSINT® safely and effectively. See full prescribing information for TIROSINT. TIROSINT® (levothyroxine sodium) capsules, for oral use Initial U.S. Approval: 2000IBSA Pharma Inc.20260325
7a7ade79-0165-4e31-b84e-667416c00c7eThese highlights do not include all the information needed to use TIROSINT® safely and effectively. See full prescribing information for TIROSINT. TIROSINT® (levothyroxine sodium) capsules, for oral use Initial U.S. Approval: 2000IBSA Pharma Inc.20250805
f4d851f6-6bf5-4ed5-8d3a-1646773c4d40These highlights do not include all the information needed to use TIROSINT® safely and effectively. See full prescribing information for TIROSINT. TIROSINT® (levothyroxine sodium) capsules, for oral use Initial U.S. Approval: 2000Akrimax Pharmaceuticals, LLC | IBSA Pambio Noranco Complex20181023

Drug Classes#

Source, Class ID, Class table
SourceClass IDClassTypeRelationshipDrug concept
ATCH03AAThyroid hormonesATC1-4levothyroxine sodium
FDASPLD013974ThyroxineCHEMhas_chemical_structurelevothyroxine
FDASPLN0000175945l-ThyroxineEPChas_epclevothyroxine
MEDRTD013974ThyroxineCHEMhas_ingredientlevothyroxine sodium
MEDRTD013974ThyroxineCHEMhas_ingredientlevothyroxine
MEDRTD000309Adrenal InsufficiencyDISEASEci_withlevothyroxine
MEDRTD000309Adrenal InsufficiencyDISEASEci_withlevothyroxine sodium
MEDRTD004342Drug HypersensitivityDISEASEci_withlevothyroxine
MEDRTD004342Drug HypersensitivityDISEASEci_withlevothyroxine sodium
MEDRTD006042GoiterDISEASEmay_treatlevothyroxine
MEDRTD006042GoiterDISEASEmay_treatlevothyroxine sodium
MEDRTD007037HypothyroidismDISEASEmay_preventlevothyroxine
MEDRTD007037HypothyroidismDISEASEmay_preventlevothyroxine sodium
MEDRTD009203Myocardial InfarctionDISEASEci_withlevothyroxine sodium
MEDRTD009203Myocardial InfarctionDISEASEci_withlevothyroxine
MEDRTD009230MyxedemaDISEASEmay_treatlevothyroxine sodium
MEDRTD009230MyxedemaDISEASEmay_treatlevothyroxine
MEDRTD013959Thyroid DiseasesDISEASEmay_diagnoselevothyroxine
MEDRTD013959Thyroid DiseasesDISEASEmay_diagnoselevothyroxine sodium
MEDRTD013964Thyroid NeoplasmsDISEASEmay_treatlevothyroxine
MEDRTD013964Thyroid NeoplasmsDISEASEmay_treatlevothyroxine sodium
MEDRTD013967Thyroiditis, AutoimmuneDISEASEmay_treatlevothyroxine sodium
MEDRTD013967Thyroiditis, AutoimmuneDISEASEmay_treatlevothyroxine
MEDRTD013971ThyrotoxicosisDISEASEmay_treatlevothyroxine
MEDRTD013971ThyrotoxicosisDISEASEci_withlevothyroxine sodium
MEDRTD013971ThyrotoxicosisDISEASEmay_treatlevothyroxine sodium
MEDRTD013971ThyrotoxicosisDISEASEci_withlevothyroxine
MEDRTN0000000237Thyroid Hormone Receptor AgonistsMOAhas_moalevothyroxine
MEDRTN0000000237Thyroid Hormone Receptor AgonistsMOAhas_moalevothyroxine sodium
MEDRTN0000008347Cellular Synthetic Activity AlterationPEhas_pelevothyroxine
MEDRTN0000008347Cellular Synthetic Activity AlterationPEhas_pelevothyroxine sodium
MEDRTN0000009340Increased GluconeogenesisPEhas_pelevothyroxine
MEDRTN0000009340Increased GluconeogenesisPEhas_pelevothyroxine sodium
MEDRTN0000009399Increased Metabolic RatePEhas_pelevothyroxine
MEDRTN0000009399Increased Metabolic RatePEhas_pelevothyroxine sodium

Properties#

Category, Property, Value table
CategoryPropertyValue
ATTRIBUTESAVAILABLE_STRENGTH0.175 MG
ATTRIBUTESGENERAL_CARDINALITYSINGLE
ATTRIBUTESHUMAN_DRUGUS
ATTRIBUTESRXNAV_HUMAN_DRUGUS
ATTRIBUTESSCHEDULE0
CODESNDANDA021924
NAMESPrescribable SynonymTirosint 175 MCG Oral Capsule
SOURCESSourceGold Standard Alchemy
SOURCESSourceMetathesaurus FDA Structured Product Labels
SOURCESSourceMicromedex RED BOOK
SOURCESSourceMultum MediSource Lexicon